New York, USA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Marginal Zone Lymphoma Market Size Expected to Demonstrate Optimal Growth in the 7MM During the Study Period (2019–2032), Analysis by DelveInsight
The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma market is categorized into three types based on the line of therapies, i.e., first-line, second-line, and third-line therapies.
DelveInsight’s Marginal Zone Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, marginal zone lymphoma emerging drugs, market share of individual therapies, and current and forecasted marginal zone lymphoma market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Marginal Zone Lymphoma Market Report
- As per DelveInsight’s analysis, the marginal zone lymphoma market is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the total incident population of non-Hodgkin lymphoma in the 7MM was estimated to be 181K in 2022. Out of these the total incident population of MZL in the 7MM in 2022 was observed to be 23K.
- Leading marginal zone lymphoma companies such as Incyte Corporation, Enterome, Bristol-Myers Squibb, CRISPR Therapeutics, Bio-Path Holdings, Inc., BeiGene, Newave Pharmaceutical Inc, IGM Biosciences, Inc., Gilead Sciences, Qilu Puget Sound Biotherapeutics (dba Sound Biologics), TG Therapeutics, Inc., Carna Biosciences, Inc., Poseida Therapeutics, Inc., Schrödinger, Inc., ArQule, Inc., Prelude Therapeutics, Genmab, AbbVie, Adicet Bio, Inc, BeiGene, VelosBio Inc., Nurix Therapeutics, Inc., Takeda, Accutar Biotechnology Inc, Xencor, Inc., Sana Biotechnology, and others are developing novel marginal zone lymphoma drugs that can be available in the marginal zone lymphoma market in the coming years.
- Some of the key therapies for marginal zone lymphoma treatment include Parsaclisib, EO2463, Nivolumab, CTX112, L-Bcl-2 antisense oligonucleotide, Zanubrutinib, LP-168, IGM-2323, Zydelig, PSB202, TG-1801, AS-1763, P-CD19CD20-ALLO1, SGR-1505, Nemtabrutinib, PRT1419, Epcoritamab, ADI-001, BGB-16673, Zilovertamab vedotin, NX-2127, 19(T2)28z1xx CAR T cells, AC676, XmAb13676, SC291, and others.
Discover which therapies are expected to grab the major marginal zone lymphoma market share @ Marginal Zone Lymphoma Market Report
Marginal Zone Lymphoma Overview
Marginal zone lymphoma (MZL) is a category of slow-growing B-cell lymphomas, making up roughly 5‒17% of all Non-Hodgkin’s Lymphoma (NHL) cases. Marginal zone lymphoma encompasses three distinct subtypes, with extranodal being the most prevalent, accounting for 50‒70% of MZL cases. The other subtypes include splenic (20%) and nodal (10%). Marginal zone lymphoma symptoms encompass fever unrelated to infection, night sweats, skin rashes, unexplained weight loss, and for nodal MZL, the possibility of painless lumps in the groin, armpit, or neck. In the case of splenic MZL, it may lead to abnormal blood counts, fatigue, and discomfort due to an enlarged spleen. To diagnose MZL, the doctor needs to conduct disease staging, which is essential for treatment planning. This process includes assessing tumor location, size, and the presence of cancer in other areas of the body.
Marginal Zone Lymphoma Epidemiology Segmentation
The marginal zone lymphoma epidemiology section provides insights into the historical and current marginal zone lymphoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The marginal zone lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of Non-Hodgkin lymphoma
- Total Marginal Zone Lymphoma Incident Cases
- Marginal Zone Lymphoma Gender-Specific Incident Cases
- Marginal Zone Lymphoma Subtype-Specific Incident Cases
- Marginal Zone Lymphoma Stage-Specific Incident Cases
Download the report to understand which factors are driving marginal zone lymphoma epidemiology trends @ Marginal Zone Lymphoma Epidemiological Insights
Marginal Zone Lymphoma Treatment Market
The choice of treatment for patients with marginal zone lymphoma depends on several factors, including the type, stage, and location of the disease. MZL can be categorized into three main subtypes: MALT/extranodal, nodal MZL, and splenic MZL. Additionally, the marginal zone lymphoma treatment approach can be classified into three lines of therapy: first-line, second-line, and third-line.
In May 2019, the FDA granted approval for the combination of lenalidomide (sold as Revlimid) and a rituximab product as a treatment option for patients who had previously received therapy for follicular lymphoma and marginal zone lymphoma. Furthermore, in December 2019, the European Commission also approved the use of Revlimid in combination with rituximab for the treatment of adult patients who had previously undergone therapy for MZL. Revlimid is categorized as an immune-modulating therapy with established anti-myeloma properties. This oral medication operates through three mechanisms, as demonstrated in both animal models and in vitro studies: it enhances the immune system's ability to identify and eliminate myeloma cells, targets and eliminates myeloma cells directly, and hinders the growth of new myeloma cells by depriving them of blood supply.
Imbruvica (ibrutinib), developed by AbbVie/Janssen Biotech/Pharmacyclics, represents a groundbreaking oral treatment, administered once daily, targeting the inhibition of a crucial protein known as Bruton’s tyrosine kinase (BTK). In January 2017, the US FDA granted approval to Imbruvica (ibrutinib) for patients dealing with relapsed/refractory marginal zone lymphoma, necessitating systemic intervention and having undergone at least one previous anti-CD20-based therapy.
Learn more about the FDA-approved drugs for marginal zone lymphoma @ Drugs for Marginal Zone Lymphoma Treatment
Key Marginal Zone Lymphoma Therapies and Companies
- Parsaclisib: Incyte Corporation
- EO2463: Enterome
- Nivolumab: Bristol-Myers Squibb
- CTX112: CRISPR Therapeutics
- L-Bcl-2 antisense oligonucleotide: Bio-Path Holdings, Inc.
- Zanubrutinib: BeiGene
- LP-168: Newave Pharmaceutical Inc
- IGM-2323: IGM Biosciences, Inc.
- Zydelig: Gilead Sciences
- PSB202: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
- TG-1801: TG Therapeutics, Inc.
- AS-1763: Carna Biosciences, Inc.
- P-CD19CD20-ALLO1: Poseida Therapeutics, Inc.
- SGR-1505: Schrödinger, Inc.
- Nemtabrutinib: ArQule, Inc.
- PRT1419: Prelude Therapeutics
- Epcoritamab: Genmab/AbbVie
- ADI-001: Adicet Bio, Inc
- BGB-16673: BeiGene
- Zilovertamab vedotin: VelosBio Inc.
- NX-2127: Nurix Therapeutics, Inc.
- 19(T2)28z1xx CAR T cells: Takeda
- AC676: Accutar Biotechnology Inc
- XmAb13676: Xencor, Inc.
- SC291: Sana Biotechnology
To know more about marginal zone lymphoma clinical trials, visit @ Marginal Zone Lymphoma Treatment Drugs
Marginal Zone Lymphoma Market Dynamics
The dynamics of the marginal zone lymphoma market are expected to change in the coming years. In recent years, an improved understanding of the complex pathobiology of MZLs has resulted in the development of novel treatment strategies. Private and government organizations have taken certain initiatives to raise awareness about the disease.
With the lifestyle change, the patient pool of MZL has been increased drastically. MZL has been associated with immune system dysregulation as a result of sustained immune stimulation from chronic infections or autoimmune disorders. Furthermore, the researchers are mainly focused on the specific treatment of MZL. So, because of the increase in the side effects and less efficacious drugs, the demand for specific therapy also increases.
Moreover, potential therapies are being investigated for the treatment of marginal zone lymphoma, and it is safe to predict that the treatment space will significantly impact the marginal zone lymphoma market during the forecast period. In addition, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the marginal zone lymphoma market in the 7MM.
However, several factors are impeding the growth of the marginal zone lymphoma market. The marginal zone lymphoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the marginal zone lymphoma market growth.
| Marginal Zone Lymphoma Report Metrics | Details |
| Study Period | 2019–2032 |
| Marginal Zone Lymphoma Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Marginal Zone Lymphoma Market Size in 2022 | USD 596 Million |
| Key Marginal Zone Lymphoma Companies | Incyte Corporation, Enterome, Bristol-Myers Squibb, CRISPR Therapeutics, Bio-Path Holdings, Inc., BeiGene, Newave Pharmaceutical Inc, IGM Biosciences, Inc., Gilead Sciences, Qilu Puget Sound Biotherapeutics (dba Sound Biologics), TG Therapeutics, Inc., Carna Biosciences, Inc., Poseida Therapeutics, Inc., Schrödinger, Inc., ArQule, Inc., Prelude Therapeutics, Genmab, AbbVie, Adicet Bio, Inc, BeiGene, VelosBio Inc., Nurix Therapeutics, Inc., Takeda, Accutar Biotechnology Inc, Xencor, Inc., Sana Biotechnology, and others |
| Key Marginal Zone Lymphoma Therapies | Parsaclisib, EO2463, Nivolumab, CTX112, L-Bcl-2 antisense oligonucleotide, Zanubrutinib, LP-168, IGM-2323, Zydelig, PSB202, TG-1801, AS-1763, P-CD19CD20-ALLO1, SGR-1505, Nemtabrutinib, PRT1419, Epcoritamab, ADI-001, BGB-16673, Zilovertamab vedotin, NX-2127, 19(T2)28z1xx CAR T cells, AC676, XmAb13676, SC291, and others |
Scope of the Marginal Zone Lymphoma Market Report
- Therapeutic Assessment: Marginal Zone Lymphoma current marketed and emerging therapies
- Marginal Zone Lymphoma Market Dynamics: Attribute Analysis of Emerging Marginal Zone Lymphoma Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Marginal Zone Lymphoma Market Access and Reimbursement
Discover more about marginal zone lymphoma drugs in development @ Marginal Zone Lymphoma Clinical Trials
Table of Contents
| 1. | Marginal Zone Lymphoma Market Key Insights |
| 2. | Marginal Zone Lymphoma Market Report Introduction |
| 3. | Marginal Zone Lymphoma Market Overview at a Glance |
| 4. | Marginal Zone Lymphoma Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Marginal Zone Lymphoma Treatment and Management |
| 7. | Marginal Zone Lymphoma Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Marginal Zone Lymphoma Marketed Drugs |
| 10. | Marginal Zone Lymphoma Emerging Drugs |
| 11. | Seven Major Marginal Zone Lymphoma Market Analysis |
| 12. | Marginal Zone Lymphoma Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Marginal Zone Lymphoma Pipeline
Marginal Zone Lymphoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key marginal zone lymphoma companies, including Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, among others.
Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin’s lymphoma companies, including Roche, Amgen, Johnson & Johnson, Novartis, among others.
Diffuse Large B-cell Lymphoma Pipeline
Diffuse Large B-cell Lymphoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diffuse large B-cell lymphoma companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis, Inc., Bayer, Kartos Therapeutics, Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio, Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio, Inc., Telios Pharma, Inc., Sorrento Therapeutics, Inc., Curocell Inc., TG Therapeutics, Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs, Inc., MEI Pharma, Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma, Inc, Newave Pharmaceutical Inc, Eden BioCell Ltd., Adicet Bio, Inc, VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics, Inc., Prelude Therapeutics, Xencor, among others.
B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others.
B-cell Lymphoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key B-cell lymphoma companies, including Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
